## Erika Adriana Eksioglu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9316249/publications.pdf

Version: 2024-02-01

41 papers

1,856 citations

331259 21 h-index 315357 38 g-index

42 all docs 42 docs citations

42 times ranked 3038 citing authors

#	Article	IF	CITATIONS
1	The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood, 2016, 128, 2960-2975.	0.6	271
2	Induction of myelodysplasia by myeloid-derived suppressor cells. Journal of Clinical Investigation, 2013, 123, 4595-4611.	3.9	254
3	TGF-Î $^2$ â $^{\circ}$ inducible microRNA-183 silences tumor-associated natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4203-4208.	3.3	178
4	Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. International Immunopharmacology, 2011, 11, 890-898.	1.7	122
5	<i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood, 2020, 136, 2812-2823.	0.6	113
6	Hepatitis C Virus Triggers Apoptosis of a Newly Developed Hepatoma Cell Line Through Antiviral Defense System. Gastroenterology, 2007, 133, 1649-1659.	0.6	100
7	Grassystatins Aâ^'C from Marine Cyanobacteria, Potent Cathepsin E Inhibitors That Reduce Antigen Presentation. Journal of Medicinal Chemistry, 2009, 52, 5732-5747.	2.9	90
8	Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene, 2013, 32, 1110-1120.	2.6	85
9	S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Leukemia, 2019, 33, 2034-2046.	3.3	66
10	The inflammatory microenvironment in MDS. Cellular and Molecular Life Sciences, 2015, 72, 1959-1966.	2.4	56
11	Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia, 2017, 31, 2172-2180.	3.3	55
12	Interleukin 12 Is Associated with Reduced Relapse without Increased Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 1014-1021.	2.0	47
13	Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematology,the, 2018, 5, e393-e402.	2.2	44
14	HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Scientific Reports, 2015, 5, 15085.	1.6	39
15	Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector Tâ€cell Function in Hepatocellular Carcinoma. Scandinavian Journal of Immunology, 2010, 72, 293-301.	1.3	36
16	Attenuation of LPS-induced inflammation by ICT, a derivate of icariin, via inhibition of the CD14/TLR4 signaling pathway in human monocytes. International Immunopharmacology, 2012, 12, 74-79.	1.7	36
17	GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Experimental Hematology, 2007, 35, 1163-1171.	0.2	34
18	Immune evasion by TGF $\hat{I}^2$ -induced miR-183 repression of MICA/B expression in human lung tumor cells. Oncolmmunology, 2019, 8, e1557372.	2.1	30

#	Article	IF	CITATIONS
19	Characterization of HCV Interactions with Toll-Like Receptors and RIG-I in Liver Cells. PLoS ONE, 2011, 6, e21186.	1.1	29
20	Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. Scientific Reports, 2016, 6, 29521.	1.6	27
21	Icariside II Induces Apoptosis of Melanoma Cells Through the Downregulation of Survival Pathways. Nutrition and Cancer, 2013, 65, 110-117.	0.9	26
22	Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 TÂcell engager, exÂvivo in MDS and melanoma. Molecular Therapy, 2022, 30, 2315-2326.	3.7	18
23	Dendritic cells as therapeutic agents against cancer. Frontiers in Bioscience - Landmark, 2010, 15, 321.	3.0	14
24	Bone Marrow Mononuclear Cells Up-Regulate Toll-Like Receptor Expression and Produce Inflammatory Mediators in Response to Cigarette Smoke Extract. PLoS ONE, 2011, 6, e21173.	1.1	14
25	Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype. Blood, 2015, 126, 144-144.	0.6	13
26	Inactivation of DAP12 in PMN Inhibits TREM1-Mediated Activation in Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0115116.	1.1	12
27	MicroRNA-155 governs SHIP-1 expression and localization in NK cells and regulates subsequent infiltration into murine AT3 mammary carcinoma. PLoS ONE, 2020, 15, e0225820.	1.1	9
28	Biological effects of <i>Byrsocarpus coccineus in vitro </i> . Pharmaceutical Biology, 2011, 49, 152-160.	1.3	7
29	Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC). Blood, 2011, 118, 788-788.	0.6	6
30	Granulocyte–macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2011, 13, 888-896.	0.3	5
31	Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC. International Journal of Molecular Sciences, 2021, 22, 1241.	1.8	5
32	Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunology, 2010, 23, 359-368.	0.6	4
33	hTERT deficiency in $na\tilde{A}^-$ ve T cells affects lymphocyte homeostasis in myelodysplastic syndrome patients. Oncolmmunology, 2013, 2, e26329.	2.1	4
34	Genomic-DNA Exposed By Somatic Gene Mutations Engages the cGAS/STING Axis to License the NLRP3 Inflammasome in Myelodysplastic Syndromes. Blood, 2018, 132, 3075-3075.	0.6	2
35	S100A9 Contributes to T Cell Dysfunction through Its Interaction with RAGE in MDS. Blood, 2019, 134, 4228-4228.	0.6	1
36	Hepatitis C Virus' initial encounters: mechanisms of innate immunity. Frontiers in Bioscience - Landmark, 2012, 17, 281.	3.0	1

#	Article	IF	CITATIONS
37	Lenalidomide and Arsenic Trioxide Have Independent Non-Interfering Effects When Used in Combination on Myeloma Cell Lines in <i>Vitro</i> . Journal of Cancer Therapy, 2013, 04, 787-796.	0.1	1
38	High Levels of Interleukin-12 Are Associated with Reduced Incidence of Relapse and Death without Increasing Acute Graft-Versus-Host Disease (AGVHD) after Allogeneic Stem Cell Transplantation (SCT) Blood, 2004, 104, 295-295.	0.6	0
39	Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody. Blood, 2014, 124, 4597-4597.	0.6	0
40	Oxidized Mitochondrial DNA Is a Catalyst and Biomarker of Pyroptotic Cell Death in Myelodysplastic Syndromes. Blood, 2018, 132, 3076-3076.	0.6	0
41	Dysregulation of Splicing Patterns in MDS Induced By the S100A9/Fto Axis. Blood, 2019, 134, 4215-4215.	0.6	0